首页> 外文OA文献 >Preserving new anthelmintics: a simple method for estimating faecal egg count reduction test (FECRT) confidence limits when efficacy and/or nematode aggregation is high.
【2h】

Preserving new anthelmintics: a simple method for estimating faecal egg count reduction test (FECRT) confidence limits when efficacy and/or nematode aggregation is high.

机译:保留新的驱虫药:当功效和/或线虫聚集度很高时,一种简单的方法来估算粪便卵数减少试验(FECRT)的置信度极限。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As it has been 30 years since a new anthelmintic class was released, it is appropriate to review management practices aimed at slowing the development of anthelmintic resistance to all drug classes. Recommendations to delay anthelmintic resistance and provide “refugia” are reviewed and a simulation model used to find optimum treatment strategies that maintain nematode control. Simulated Australian conditions indicated that a common successful low-risk treatment program was a rapid rotation between a “triple-combination” product (benzimidazole + levamisole + abamectin) and a new high-efficacy drug (monepantel). Where Haemonchus contortus was a threat, moxidectin was required at critical times because of its persistent activity against this parasite. Leaving up to 4% of adult sheep untreated provided sufficient “refugia” for non-selected worms to reduce the risk of selecting for anthelmintic resistance without compromising nematode control.ududFor a new anthelmintic, efficacy estimated by faecal egg count reduction (FECR) is likely to be at or close to 100%, however using current methods the 95% confidence limits (CL) for 100% are incorrectly determined as 100%. The fewer eggs counted pre-treatment, the more likely an estimate of 100% will occur, particularly if the true efficacy is >90%. A novel way to determine the lower-CL (LCL) for 100% efficacy is to reframe FECR as a binomial proportion, i.e. define: n and x as the total number of eggs counted (rather than eggs per gram of faeces) for all pre-treatment and post-treatment animals, respectively; p the proportion of resistant eggs is p = x/n and percent efficacy is 100*(1-p) (assuming equal treatment group sizes and detection levels, pre- and post-treatment). The LCL is approximated from the cumulative inverse beta distribution by: 95%LCL = 100*(1-(BETAINV(0.975,x + 1,n-x + 1))). This method is simpler than the current method, independent of the number of animals tested, and demonstrates that for 100% efficacy at least 37 eggs (not eggs per gram) need to be counted pre-treatment before the LCL can exceed 90%. When nematode aggregation is high, this method can be usefully applied to efficacy estimates lower than 100%, and in this case the 95% upper-CL (UCL) can be estimated by:udud95%UCL = 100*(1-(BETAINV(0.025,x + 1,n-x + 1))), with the LCL approximated as described above. A simulation study to estimate the precision and accuracy of this method found that the more conservative 99%CL was optimum; in this case 0.975 and 0.025 are replaced by 0.995 and 0.005 to estimate the LCL and UCL, respectively.
机译:自新的驱虫药类发布以来已有30年了,因此有必要审查旨在减缓对所有药物类别的驱虫药耐药性发展的管理实践。审查了延迟驱虫药抗药性和提供“避难所”的建议,并通过仿真模型找到了维持线虫控制的最佳治疗策略。模拟的澳大利亚情况表明,成功的常见低风险治疗方案是在“三联组合”产品(苯并咪唑+左旋咪唑+阿维菌素)和新的高效药物(monepantel)之间快速轮换。在扭曲的弯头梭菌(Haemonchus contortus)受到威胁的情况下,由于它对这种寄生虫的持续活性,因此在关键时刻需要莫昔克丁。留下多达4%的未经处理的成年绵羊为未选择的蠕虫提供了足够的“避难所”,从而降低了选择驱虫药耐药性的风险而又不损害线虫的控制。 ud ud对于一种新的驱虫药,其功效是通过减少粪便卵数(FECR)来评估的)可能会达到或接近100%,但是使用当前方法,将100%的95%置信度限制(CL)错误地确定为100%。治疗前计数的卵子越少,估计100%发生的可能性就越大,特别是如果实际功效> 90%时。确定100%功效的较低CL(LCL)的一种新颖方法是将FECR重新构造为二项式比例,即,定义:n和x为所有前代计数的卵总数(而不是每克粪便中的卵数) -分别处理动物和后处理动物; p抗性卵的比例为p = x / n,功效百分比为100 *(1-p)(假设治疗组大小和检测水平相等,治疗前后)。 LCL从累积的反向beta分布近似为:95%LCL = 100 *(1-(BETAINV(0.975,x + 1,n-x + 1)))。该方法比当前方法更简单,不受测试动物的数量的影响,并且表明,对于100%的功效,在LCL超过90%之前,至少需要对37个卵(每克卵数)进行计数。当线虫聚集度很高时,此方法可有效地应用于功效估计值低于100%的情况,在这种情况下,可以通过以下方式来估计95%的上CL(UCL): ud ud95%UCL = 100 *(1- (BETAINV(0.025,x + 1,nx + 1))),且LCL如上所述。通过仿真研究来估算此方法的精度和准确性,发现比较保守的99%CL是最佳选择。在这种情况下,分别用0.995和0.005代替0.975和0.025来估算LCL和UCL。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号